549 Causes of death and risk of secondary malignant tumours in patients with malignant tumours of the small bowel

1995 ◽  
Vol 31 ◽  
pp. S117
Author(s):  
N. Zar ◽  
J. Rastad ◽  
J. Yuen ◽  
L. Holmberg
2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e21503-e21503
Author(s):  
Han Hsi Wong ◽  
Rajani Chengal ◽  
Richard Hardwick ◽  
Gail Horan ◽  
Helen Hatcher ◽  
...  

e21503 Background: Historically, GISTs were often misdiagnosed as other tumours. However, with the increasing awareness of GISTs, one needs to be careful in confirming the diagnosis since other tumours can simulate GISTs on endoscopy/imaging/histology. We report our 8 year experience of GIST mimics from the CGSG database. Methods: 250 cases discussed in the specialist multidisciplinary meeting from 2004 – 2012 were reviewed. Tumours initially suspected to be GISTs but turned out to be other tumours were included in this analysis. Patient demographics, endoscopic, imaging and histological features were analysed in 41 GIST mimics. Central review by specialist histopathologist was undertaken with immunohistochemical and molecular analysis to differentiate these tumours from GISTs. Results: GIST mimics N= 41. Median age 56 years (range 11 – 82 years), male:female ratio 1:1. Median size 8 cm (range 1.9 – 30 cm). Site of origin of tumours: stomach 34%, oesophagus/junction 15%, mesentery 12%, small bowel 10%, colon 5%, retroperitoneum 5%, pancreas 5%, liver 2% and indeterminate site of origin 12%. Suspicion of GIST was raised from imaging (46%), endoscopy (41%) and histology (39%). The histological subtypes of GIST mimics are summarised in the Table. Conclusions: Many benign and malignant tumours do mimic GISTs on imaging/endoscopy or histology. The diagnosis of GISTs should be made by a specialist multidisciplinary team with experience in imaging and histopathology. Distinguishing GISTs from their mimics is of critical importance both for prognosis and management. [Table: see text]


2021 ◽  
Vol 14 (9) ◽  
pp. e244381
Author(s):  
Mohammed Fawaz ◽  
Kamal Kataria ◽  
Ankita Singh ◽  
Saugata Samadder

Small bowel malignant tumours make only 2% of all gastrointestinal (GI) malignancies. Small bowel leiomyosarcoma (LMS) is further rare, accounts for only 0.1%–3% fraction of these tumours. These cases can present as asymptomatic intra-abdominal mass, anaemia due to GI bleed or acute abdomen such as perforation peritonitis, intussusception and bowel ischaemia. Standard of care is surgical resection. Our case presented as large lobulated exophytic ileal LMS measuring 10.8×11×14.7 cm involving multiple small bowel loops and abutting right iliac vessels and uterus. Patient’s clinical course was complicated with COVID-19 positivity, deep vein thrombosis and pulmonary thromboembolism. She was managed by preoperative anticoagulation followed by resection of the tumour with end ileostomy.


2020 ◽  
pp. jclinpath-2020-207080
Author(s):  
Elias Mund ◽  
Johannes Salem ◽  
Hans H Kreipe ◽  
Kais Hussein

AimsThe number of clinical autopsies decreases while the rate of missed relevant diagnoses is known to be 2%–20%. In this study, we focused on postmortem examinations of patients after transplantation of solid organs.MethodsA total of 122 cases were assessed for this study. Transplant organs included liver (LiTx; n=42/122, 34%), heart (n=8/122, 7%), lungs (n=32/122, 26%), kidney (KTx; n=38/122, 31%) and KTx+LiTx (n=2/122, 2%).ResultsThe most frequent autopsy-verified causes of death were cardiac or respiratory failure (together n=85/122, 70%). The frequency of malignant tumours that were identified at autopsy was 5% (n=6/122). In 3% (n=4/122) of cases, Goldman class I discrepancies between clinical diagnosis and autopsy findings were identified.ConclusionsThe rate of missed relevant diagnoses might be relatively low, but these cases nevertheless refute the contention that modern diagnostic techniques negate the need for autopsies in patients who died after transplantation.


2019 ◽  
Vol 121 (10) ◽  
pp. 883-889 ◽  
Author(s):  
Kwok F. Wong ◽  
Paul C. Lambert ◽  
Sarwar I. Mozumder ◽  
John Broggio ◽  
Mark J. Rutherford

Abstract Background Cancer survival statistics are typically reported by using measures discounting the impact of other-cause mortality, such as net survival. This is a hypothetical measure and is interpreted as excluding the possibility of cancer patients dying from other causes. Crude probability of death partitions the all-cause probability of death into deaths from cancer and other causes. Methods The National Cancer Registration and Analysis Service is the single cancer registry for England. In 2006–2015, 1,590,477 malignant tumours were diagnosed for breast, colorectal, lung, melanoma and prostate cancer in adults. We used a relative survival framework, with a period approach, providing estimates for up to 10-year survival. Mortality was partitioned into deaths due to cancer or other causes. Unconditional and conditional (on surviving 1-years and 5-years) crude probability of death were estimated for the five cancers. Results Elderly patients who survived for a longer period before dying were more likely to die from other causes of death (except for lung cancer). For younger patients, deaths were almost entirely due to the cancer. Conclusion There are different measures of survival, each with their own strengths and limitations. Careful choices of survival measures are needed for specific scenarios to maximise the understanding of the data.


1994 ◽  
Vol 3 (2) ◽  
pp. 61-68 ◽  
Author(s):  
J.H. Donohue

1950 ◽  
Vol 16 (2) ◽  
pp. 425-439
Author(s):  
M.A. Spellberg ◽  
Edward L. Jackson
Keyword(s):  

1954 ◽  
Vol 27 (5) ◽  
pp. 565-577 ◽  
Author(s):  
John F. Scholer ◽  
Charles F. Code

Sign in / Sign up

Export Citation Format

Share Document